France Non Invasive Prenatal Testing Market

ID: MRFR/MED/49125-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
France Non-Invasive Prenatal Testing Market Research Report By Test Type (Cell-Free DNA Testing, Biochemical Testing, Combined Screening), By Application (Fetal Gender Determination, Chromosomal Abnormalities Screening, Rhesus Disease Screening), By Technology (Next Generation Sequencing, Microarray Analysis, Polymerase Chain Reaction) and By End User (Hospitals, Diagnostic Laboratories, Direct-to-Consumer Companies) - Growth & Industry Forecast 2025 To 2035
France Non Invasive Prenatal Testing Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)12.09%
2024 Market Size$ 98.28 Million
2025 Market Size$ 110.16 Million
2035 Market Size$ 345 Million
Key Players
Illumina
Roche
Natera
Fulgent Genetics
LabCorp
Quest Diagnostics
Trends
  • Technological Advancements
  • Regulatory Support
  • Patient Awareness and Demand
Opportunities
  • Rising Birth Rates
  • Technological Innovations
  • Insurance Coverage Expansion
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Life Sciences, BY Type (USD Million)
      1. 4.1.1 Cell-Free Fetal DNA Testing
      2. 4.1.2 Biochemical Markers Testing
      3. 4.1.3 Ultrasound Screening
    2. 4.2 Life Sciences, BY Application (USD Million)
      1. 4.2.1 Trisomy Detection
      2. 4.2.2 Single Gene Disorders
      3. 4.2.3 Sex Chromosome Abnormalities
    3. 4.3 Life Sciences, BY Technology (USD Million)
      1. 4.3.1 Next-Generation Sequencing
      2. 4.3.2 Microarray Analysis
      3. 4.3.3 Massively Parallel Sequencing
    4. 4.4 Life Sciences, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Diagnostic Laboratories
      3. 4.4.3 Research Institutions
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Life Sciences
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Illumina (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Natera (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Fulgent Genetics (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 LabCorp (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Quest Diagnostics (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 HaploX (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Genomic Health (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 FRANCE MARKET ANALYSIS BY TYPE
    3. 6.3 FRANCE MARKET ANALYSIS BY APPLICATION
    4. 6.4 FRANCE MARKET ANALYSIS BY TECHNOLOGY
    5. 6.5 FRANCE MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
    9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
    11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
    12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
    13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
    16. 6.16 LIFE SCIENCES, BY TECHNOLOGY, 2024 (% SHARE)
    17. 6.17 LIFE SCIENCES, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    18. 6.18 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
    19. 6.19 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

France Non Invasive Prenatal Testing Market Segmentation

France Non Invasive Prenatal Testing Market By Type (USD Million, 2025-2035)

  • Cell-Free Fetal DNA Testing
  • Biochemical Markers Testing
  • Ultrasound Screening

France Non Invasive Prenatal Testing Market By Application (USD Million, 2025-2035)

  • Trisomy Detection
  • Single Gene Disorders
  • Sex Chromosome Abnormalities

France Non Invasive Prenatal Testing Market By Technology (USD Million, 2025-2035)

  • Next-Generation Sequencing
  • Microarray Analysis
  • Massively Parallel Sequencing

France Non Invasive Prenatal Testing Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.